Abbott Laboratories (ABT) : Dempze Nancy E scooped up 900 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 24,300 shares of Abbott Laboratories which is valued at $1,094,715.Abbott Laboratories makes up approximately 1.88% of Dempze Nancy E’s portfolio.
Other Hedge Funds, Including , Delaney Dennis R boosted its stake in ABT in the latest quarter, The investment management firm added 334 additional shares and now holds a total of 40,732 shares of Abbott Laboratories which is valued at $1,834,977. Abbott Laboratories makes up approx 3.82% of Delaney Dennis R’s portfolio. Sivik Global Healthcare sold out all of its stake in ABT during the most recent quarter. The investment firm sold 125,000 shares of ABT which is valued $5,657,500.Condor Capital Management boosted its stake in ABT in the latest quarter, The investment management firm added 6,760 additional shares and now holds a total of 69,624 shares of Abbott Laboratories which is valued at $3,151,182. Abbott Laboratories makes up approx 0.72% of Condor Capital Management’s portfolio.Blue Fin Capital reduced its stake in ABT by selling 250 shares or 1.34% in the most recent quarter. The Hedge Fund company now holds 18,435 shares of ABT which is valued at $824,966. Abbott Laboratories makes up approx 0.67% of Blue Fin Capital’s portfolio.Osborne Partners Capital Management reduced its stake in ABT by selling 2,537 shares or 1.4% in the most recent quarter. The Hedge Fund company now holds 179,321 shares of ABT which is valued at $7,648,041. Abbott Laboratories makes up approx 1.10% of Osborne Partners Capital Management’s portfolio.
Abbott Laboratories opened for trading at $45.2 and hit $45.23 on the upside on Monday, eventually ending the session at $45.15, with a gain of 0.24% or 0.11 points. The heightened volatility saw the trading volume jump to 65,25,830 shares. Company has a market cap of $66,370 M.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.